Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC) (ERLOPET)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Lung Cancer Group Cologne.
Recruitment status was  Active, not recruiting
Information provided by:
Lung Cancer Group Cologne Identifier:
First received: December 5, 2007
Last updated: September 16, 2009
Last verified: September 2009